💊

Sutent

sunitinib

Tumori stromali gastrointestinali; Carcinoma a cellule renali; Tumori neuroendocrini

✅ Autorizzato

✅

Nessun allarme attivo

Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.

A cosa serve

Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with Sutent as first-line treatment is limited (see section 5.1).

⚠️ Sicurezza del paziente

Pagina ufficiale EMA

https://www.ema.europa.eu/en/medicines/human/EPAR/sutent